title: Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.
abstract: Niacin (nicotinic acid) reduces cardiovascular events in patients with dyslipidemia. However, symptoms associated with niacin-induced vasodilation (e.g., flushing) have limited its use. Laropiprant is a selective antagonist of the prostaglandin D(2) receptor subtype 1 (DP1), which may mediate niacin-induced vasodilation. The aim of this proof-of-concept study was to evaluate the effects of laropiprant (vs placebo) on niacin-induced cutaneous vasodilation. Coadministration of laropiprant 30, 100, and 300 mg with extended-release (ER) niacin significantly lowered flushing symptom scores (by approximately 50% or more) and also significantly reduced malar skin blood flow measured by laser Doppler perfusion imaging. Laropiprant was effective after multiple doses in reducing symptoms of flushing and attenuating the increased malar skin blood flow induced by ER niacin. In conclusion, the DP1 receptor antagonist laropiprant was effective in suppressing both subjective and objective manifestations of niacin-induced vasodilation.
authors: Department of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey, USA. eseng_lai@merck.com
authors: E
authors: E
authors: Lai
authors: I
authors: I
authors: De Lepeleire
authors: T M
authors: TM
authors: Crumley
authors: F
authors: F
authors: Liu
authors: L A
authors: LA
authors: Wenning
authors: N
authors: N
authors: Michiels
authors: E
authors: E
authors: Vets
authors: G
authors: G
authors: O'Neill
authors: J A
authors: JA
authors: Wagner
authors: K
authors: K
authors: Gottesdiener
mesh_terms: D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000494:pharmacology; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000008:administration & dosage / Q000009:adverse effects*; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D012039:Regional Blood Flow; D012867:Skin / Q000098:blood supply; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D003692:Delayed-Action Preparations; D007211:Indoles; C518174:MK-0524; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D014665:Vasodilator Agents; D009525:Niacin; D001241:Aspirin; C036293:prostaglandin D2 receptor